Medicare Enrolled
Dr. Anthony Al-Dehneh, D.O.
Cardiovascular Disease · Crestview, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Al-Dehneh from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Al-Dehneh? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Al-Dehneh
Dr. Anthony Al-Dehneh is a cardiovascular disease in Crestview, FL, with 19 years in practice. Based on federal Medicare data, Dr. Al-Dehneh performed 16,046 Medicare services across 10,143 unique beneficiaries.
Between the years covered by Open Payments, Dr. Al-Dehneh received a total of $22,623 from 40 pharmaceutical and/or device companies across 342 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Al-Dehneh is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 3% volume in FL$ $22,623 industry payments
Medicare Practice Summary
Medicare Utilization ↗16,046
Medicare services
Top 3% in FL for cardiovascular disease
10,143
Unique beneficiaries
$79
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~845 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) | 4,618 | $90 | $191 |
| Regadenoson injection (Lexiscan) for heart stress test | 1,496 | $43 | $92 |
| Echocardiogram, transthoracic | 1,412 | $83 | $367 |
| Electrocardiogram (EKG), 12-lead | 1,160 | $10 | $46 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 839 | $223 | $288 |
| Hospital follow-up visit, moderate complexity | 531 | $62 | $128 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 527 | $21 | $50 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 525 | $28 | $100 |
| Remote pacemaker/defibrillator monitoring, 90 days | 432 | $17 | $60 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 419 | $326 | $859 |
| Remote pacemaker monitoring, 90 days | 323 | $23 | $65 |
| Prothrombin time test (blood clotting) | 307 | $4 | $21 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 208 | $64 | $181 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 198 | $10 | $22 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 187 | $20 | $47 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 173 | $14 | $26 |
| EKG interpretation and report | 169 | $6 | $25 |
| New patient office visit (45-59 min) | 167 | $119 | $291 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 163 | $10 | $40 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 158 | $50 | $275 |
| Cardiac catheterization | 153 | $201 | $606 |
| Initial hospital admission, moderate complexity | 147 | $103 | $246 |
| Office visit, established patient (20-29 min) | 141 | $70 | $130 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 112 | $28 | $121 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 110 | $16 | $43 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) | 109 | $27 | $113 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 100 | $133 | $416 |
| Ultrasound of both sides of head and neck blood flow | 90 | $130 | $420 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 77 | $17 | $48 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | 76 | $6 | $41 |
| Programming of dual lead pacemaker system | 75 | $61 | $124 |
| External shock to heart to regulate heart beat | 67 | $85 | $400 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 61 | $91 | $279 |
| Ultrasound of heart with probe in esophagus, with report | 59 | $80 | $194 |
| Electrocardiogram (ecg) 2-day continuous | 55 | $12 | $70 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 55 | $13 | $47 |
| Ultrasound of heart, follow-up | 54 | $44 | $146 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 54 | $11 | $82 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 53 | $11 | $79 |
| Ultrasound of heart blood flow, valves and chambers | 48 | $14 | $33 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 43 | $19 | $45 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 41 | $600 | $1,476 |
| Coronary stent placement | 40 | $443 | $1,146 |
| Laser destruction of incompetent vein of arm or leg using imaging guidance | 31 | $759 | $2,105 |
| Ultrasound evaluation of heart blood vessel during diagnosis or treatment, initial vessel | 30 | $58 | $171 |
| Complete ultrasound study of arm and leg arteries | 28 | $88 | $324 |
| Hospital follow-up visit, high complexity | 27 | $94 | $184 |
| Initial hospital admission, high complexity | 24 | $137 | $361 |
| Ultrasound of leg arteries or artery grafts | 20 | $171 | $504 |
| Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | 19 | $240 | $681 |
| Programming of multiple lead implantable defibrillator system | 18 | $82 | $176 |
| Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | 17 | $263 | $758 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
17.1% high complexity
18.2% medium
64.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$22,623
Total received (2018-2024)
Avg $3,232/year across 7 years
Top 13% in FL for cardiovascular disease
40
Companies
342
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$21,111 (93.3%)
Scientific / Research
Research funding and grants
$1,512 (6.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,641
2023$1,484
2022$6,317
2021$998
2020$3,103
2019$3,584
2018$2,494
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Medtronic Vascular, Inc.
$4,137
Penumbra, Inc.
$2,929
Abbott Laboratories
$2,854
Edwards Lifesciences Corporation
$2,047
Medtronic, Inc.
$1,638
Cardiovascular Systems Inc.
$1,413
Boston Scientific Corporation
$1,272
W. L. Gore & Associates, Inc.
$838
Amgen Inc.
$788
AstraZeneca Pharmaceuticals LP
$621
Novartis Pharmaceuticals Corporation
$550
PFIZER INC.
$535
Merck Sharp & Dohme LLC
$345
Inari Medical, Inc.
$326
ABIOMED
$317
Boehringer Ingelheim Pharmaceuticals, Inc.
$286
Janssen Pharmaceuticals, Inc
$250
E.R. Squibb & Sons, L.L.C.
$210
Shockwave Medical, Inc
$188
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$164
Gilead Sciences, Inc.
$140
Esperion Therapeutics, Inc.
$102
CVRx, Inc.
$92
Kestra Medical Technology Services, Inc.
$70
ZOLL Circulation Inc
$68
Bard Peripheral Vascular, Inc.
$66
SANOFI-AVENTIS U.S. LLC
$60
Amarin Pharma Inc.
$50
Endologix LLC
$50
BTG International, Inc.
$35
CARDIVA MEDICAL, INC.
$33
AngioDynamics, Inc.
$27
Philips Electronics North America Corporation
$22
Kiniksa Pharmaceuticals, Ltd.
$20
SCPHARMACEUTICALS INC.
$17
Biosense Webster, Inc.
$15
Chiesi USA, Inc.
$13
ARALEZ PHARMACEUTICALS US INC.
$12
Kowa Pharmaceuticals America, Inc.
$11
EKOS Corporation
$11
Top 3 companies account for 43.8% of total payments
Associated products mentioned in payments ›
(5091) Amb Mon & Diag Und · 3F · AMPLATZER AMULET · AURYON LASER SYSTEM 100-120 VAC · Arcalyst · Assure WCD · BRILINTA · Barostim Neo System · CAMZYOS · CARDIVA VASCADE MVP VVCS 6-12F · CARTO 3 · CHANTIX · COREVALVE EVOLUT R · CoreValve Evolut · Corlanor · Diamondback Peripheral · EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) · EKOSONIC · ELIQUIS · ENTRESTO · FARXIGA · FLOWTRIEVER CATHETER · FUROSCIX · Fox Sv PTA catheter and Armada 14 percutaneous catheter and Viatrac 14 Plus peripheral catheter · GENERAL - STRUCTURAL HEART · GORE CARDIOFORM Septal Occluder · Impella · Indigo System · JARDIANCE · KENGREAL · LEQVIO · LINQ II · LUTONIX Drug Coated Balloon · LifeVest · Livalo · MITRACLIP · MULTAQ · Micra · MitraClip System · NEXLIZET · OPTIS · PASCAL · PRADAXA · PRALUENT · Peripheral Orbital Atherectomy System · Quadra Assura CRT Defibrillator · RUBY Coil · Repatha · Rotarex · RotarexS 6 F x 135 cm · S · Tendril Pacing Lead · TherOx DS2 Console · Torus Stent Graft System · VARITHENA · VERQUVO · VYNDAQEL · Vascepa · Vascular Lithotripsy · WATCHMAN · WATCHMAN FLX · XARELTO · ZONTIVITY
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $141 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
11
Per 100K population
5.1
County median income
$79,097
Nearest hospital
NORTH OKALOOSA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Al-Dehneh is a clinical cardiology specialist, with above-average Medicare volume (top 3% in FL), and high industry engagement (low-engagement, top 13%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Al-Dehneh experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Al-Dehneh performed 4,618 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Al-Dehneh receive payments from pharmaceutical companies?
Yes. Dr. Al-Dehneh received a total of $22,623 from 40 companies across 342 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Al-Dehneh's costs compare to other cardiovascular diseases in Crestview?
Dr. Al-Dehneh's average Medicare payment per service is $79. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Al-Dehneh) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Crestview
Browse cardiovascular diseases in Crestview ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in FL
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in FL
Which FL cardiovascular diseases receive the most from drug and device companies.
By company
Medtronic Vascular, Inc. Payments to Doctors
See all physicians who received payments from Medtronic Vascular, Inc..
By company
Penumbra, Inc. Payments to Doctors
See all physicians who received payments from Penumbra, Inc..
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology